ALKS 4230-003 (Alkermes Inc. ) Description: Clinical and Immunologic Activity of Nemvaleukin Alfa With a less Frequent IV Dosing With Pembrolizumab and Impact on Tumor Microenvironment in Soloid Tumor Patients (Artistry-3) Target Patient Population: Cutaneous melanoma, Renal Cell, Triple Negative Breast, MMS Colorectal, Ovarian and any MSI-High solid tumors Study Design: Study drug is
Clinical Trial Type: Breast
AstraZeneca D9268C00001 (TROPION-Breast01)
A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) PI: Amy VanderWoude Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint
AstraZeneca SERENA-6
A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor (SERENA-6) Principal Investigator:
Genentech (CELESTIMO)
eFT226-0002 (Effector Therapeutics)
eFT226-0002 (Effector Therapeutics) Description: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with Selected Advanced Solid Tumor Malignancies Target Population: . ER positive breast cancer with FGFR amplifications, and NSCLC with KRAS G12C mutations (in combination with Sotorasib) Study Design: In Dose Escalation Study drug is administered IV weekly.
GENMAB (GCT1046-04)
GENMAB (GCT1046-04) A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor PI: Dr. Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at
C4161001 (Pfizer)
Description: Phase 1/2a Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of PF-07104091 as a Single Agent and in Combination Therapy. Target Patient Population: Small cell Lung Cancer, Platinum Resistant Ovarian, Non-small cell Lung Cancer; in combination with palbociclib and fulvestrant for HR+ HER2- Metastatic Breast Cancer (3rd
C4391001 ( Pfizer)
Description: A Phase 1/1B Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07220060 as a Single Agent and As Part of Combination Therapy In Participants With Advanced Solid Tumors. Target Patient Population: Metastatic Breast Cancer, NSCLC (adeno), Prostate cancer, Colorectal cancer, Liposarcoma and tumor types with CDK4 or CCND1 amplification; in
C4391002 (Pfizer)
Description: Phase 1B/2, Open Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in participants with Advanced Solid Tumor Target Patient Population: All solid tumors, but is especially attractive for HR+, HER2- breast cancer Study Design:
SGN B7H4V-001 (Seagen, Inc.)
Description: A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors Target Patient Population: Ovarian, Primary peritoneal or Fallopian, Breast (HER2-, HR+), Triple Negative Breast, Endometrial, Squamous Non Small Cell Lung, Cholangiocarcinoma, Gallbladder cancers. Study Design: Drug is administered IV 21 day cycle (Day 1, 8 or Day 1 only)